Neoadjuvant mFOLFIRINOX Studied for Borderline Resectable PDAC
For patients with borderline resectable pancreatic ductal adenocarcinoma, favorable overall survival seen with eight cycles of mFOLFIRINOX
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.